A newly FDA-approved therapy is offering a different approach for patients with platinum-resistant ovarian cancer—an area ...
Dr Komrokji explains how the IPSS-M improves prognostic precision in MDS but cautions that upstaging alone should not ...
However, since CD38 antibody exposure is now standard of care for both transplant-eligible and ineligible populations in 2026 ...
Lilit Karapetyan, MD, MS, discusses a single-center trial of reduced-intensity conditioning before tumor-infiltrating ...
The FDA has agreed on the design of two randomized phase 3 trials evaluating CRB-701, a next-generation Nectin-4-targeted ...
In this final segment, the discussion turns to practical challenges patients face during first-line treatment with ...
Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ...
T-cell therapy has transformed the treatment landscape for patients with relapsed or refractory large B-cell lymphoma (LBCL), ...
Dr Simone’s research focuses on utilizing advanced modalities like proton therapy to mitigate morbidity. Unlike standard ...
In this segment on advanced renal cell carcinoma, Dr. McGregor explores the role of VEGFR TKI monotherapy in patients with favorable risk disease, where NCCN guidelines include both IO-TKI ...
In this segment on advanced renal cell carcinoma, Dr. Wulff focuses on the role of cabozantinib across different treatment settings and how clinicians decide between monotherapy and combination ...
According to a recent systematic review published in JCO Oncology Practice, implementation of same-day multidisciplinary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results